Search 

see company website

VISEN Pharmaceuticals, headquartered in Shanghai, China, is committed to the treatment of endocrine-related disease, introducing the world’s leading treatment methods and drugs into the China market, benefiting Chinese patients while unleashing product potential.

VISEN Pharmaceuticals (VISEN) was formed by Ascendis Pharma A/S (Nasdaq: ASND) and an investor syndicate led by Vivo Capital (along with participation by Sofinnova Ventures), to develop and commercialize Ascendis Pharma’s endocrinology rare disease therapies in Greater China. The pipeline of VISEN covers pediatric endocrinology, adult endocrinology, and rare disease. VISEN management team has extensive experience in the development and commercialization of endocrine disease products in Greater China. VISEN has a deep understanding of unmet medical needs in Chinese patients and is actively expanding its pipeline through in-licensing and partnership.

Wanbang Biopharmaceuticals (Wanbang Biopharma) is a core member of Shanghai Fosun PHARMACEUNCAL (group) Co., Ltd.(Fosun Pharma”, Stock code: 600196-SH,02196-HK).

Wuxi High-tech zone is focusing on developing biopharmaceutical industry. It is one of the top high-tech zones in China. There are a number of famous biopharmaceutical companies such as AstraZeneca, Wuxi AppTech.

XuanZhu Biopharma is a clinical stage, biotechnology company wholly owned by Sihuan Pharmaceutical Holdings Group. We are focused on bringing to market first-in-class therapies for unmet and underserved patient populations. Our therapeutic areas include oncology and metabolic/liver diseases. The cornerstone of our oncology franchise is Birociclib (CDK 4/6i). We have seven programs in clinical development all of which we expect to launch within the next seven years with expected revenues reaching $400 M by 2025 and exceeding $1 B by 2030. XuanZhu has closed its Series A financing in August 2020, raising a total of ¥800 M (~ $118 M)

江苏紫龙药业有限公司成立于2012年,由国家重点医药企业扬子江药业集团投资建设,是一家集
生产、质量、研发、推广于一体的现代化综合性制药企业。紫龙药业位于江苏省常州市新北区生命健
康产业园区内,紧靠沪宁高速、江宜高速、常州高铁站以及奔牛机场,地理位置得天独厚。总投资达
到16亿元,项目用地面积344亩,现有员工400余人。主要生产剂型包括：固体制剂、小容量注射剂、
冻干粉针剂等。截至目前,紫龙药业生产车间已全部通过新版GMP认证。

na

Yngzijiang Pharmaceutial Group is an integrated healthcare company in china, our business scope ranges from Pharma(small molcules,biological and TCM), Medical Device and consumer health products. With nearly 20000 employees around the world. We are the biggest private Pharmaceutial company by revenue in China, with a strong revenue growth rate in the past decade. We are open to any coopearation opportunities globally. Welcome to talk to us.

隶属于浙江亚太药业股份有限公司,位于武汉光谷,从事新药研发、仿制药开发、临床研究服务等